Skip to main content

Table 3 Methylation markers by patient characteristics

From: NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas

  CCNA1 NDN CD1A DCC p16 GADD45
  median (range) p median (range) p median (range) p median (range) p median (range) p median (range) p
Age             
 <40 years 19.5 (14.5, 64.7) 0.4 40.8 (34.5, 72.8) 0.4 78.6 (56.8, 91.2)) 0.02 21.3 (9.9, 62.3) 0.4 3.1 (0.6, 25.0) 0.5 1.5 (1.0, 2.8) 0.5
 40-60 25.8 (3.0, 90.5)   44.6 (10.8, 84.2)   71.0 (22.2, 93.9)   33.2 (3.1, 85.8)   2.3 (0, 70.1)   1.4 (0, 3.9)  
 ≥60 27.3 (5.5, 77.0)   43.9 (11.2, 84.9)   68.6 (21.4, 90.9)   33.7 (3.0, 79.8)   2.2 (0, 59.8)   1.4 (0, 16.0)  
HPV             
 Positive 33.3 (3.0, 76.0) <0.001 52.7 (14.0, 84.9) <0.001 77.6 (25.1, 93.9) <0.001 44.7 (3.1, 85.8) <0.001 1.9 (0, 59.8) <0.001 1.4 (0.4, 3.9) 0.8
 Negative 20.9 (5.5, 90.5)   40.0 (10.8, 80.3)   65.4 (21.4 (92.2)   26.0 (3.0, 83.3)   2.5 (0, 70.1)   1.4 (0, 16)  
Pack Years             
 0 26.6 (3.0, 90.5) 0.2 46.4 (14.0, 84.2) 0.01 79.7 (47.2, 93.9) <0.001 36.7 (3.1, 79.8) 0.1 2.2 (0, 26.9) 0.7 1.5 (0.3, 3.7) 0.2
 0-10 31.5 (13.3, 63.3)   45.9 (24.6, 75.7)   70.5 (32.4, 91.1)   40.5 (10.8, 71.7)   2.1 (0, 46.6)   1.4 (0.4, 16.0)  
 10-20 23.6 (6.8, 64.8)   46.4 (10.8, 76.8)   73.0 (26.7, 91.7)   32.7 (6.1, 75.1)   2.2 (0, 70.1)   1.6 (0.7, 3.9)  
 20+ 25.5 (6.3, 77.0)   41.3 (11.2, 84.9)   64.2 (21.4, 92.0)   31.4 (3.0, 85.8)   2.4 (0, 59.8)   1.4 (0, 3.9)  
Tobacco             
 Current 25.5 (6.3, 76.0) 0.8 45.0 (10.8, 84.9) 0.02 69.5 (25.1, 91.7) <0.001 39.5 (4.2, 83.3) 0.03 2.2 (0, 70.1) 0.7 1.4 (0, 16) 0.5
 Former 25.6 (6.8, 77.0)   42.2 (11.2, 80.3)   64.4 (21.4, 90.0)   29.3 (3.0, 85.8)   2.4 (0, 46.6)   1.4 (0, 3.9)  
 Never 26.6 (3, 90.5)   46.4 (14.0, 84.2)   79.7 (47.2, 93.9)   35.7 (3.1, 79.8)   2.2 (0, 26.9)   1.5 (0.3, 3.7)  
Site             
 Larynx/Glottic 24.5 (8.0, 90.5) <0.001 41.2 (11.2, 84.9) <0.001 56.2 (21.6, 92.2) <0.001 26.3 (3.1, 83.3) <0.001 2.4 (0, 51.8) <0.001 1.4 (0, 3.9) 0.02
 Oral Cavity 22.0 (5.5, 77.0)   40.0 (10.8, 62.8)   70.6 (21.4, 90.2)   28.4 (3.0, 67.2)   2.6 (0, 70.1)   1.4 (0, 16.0)  
 Oropharynx 32.3 (3.0, 76.0)   52.7 (21.8, 84.2)   77.5 (21.6, 93.9)   42.5 (6.1, 81.6)   2.0 (0, 39.9)   1.4 (0.4, 3.9)  
 Hypopharynx 15.6 (9.0, 64.0)   44.2 (17.2, 91.0)   60.5 (25.1, 90.6)   54.5 (12.3, 85.8)   2.6 90, 59.8)   1.1 (0, 1.6)  
Stage             
 I/Cis 27.5 (11.8, 77.0) 0.01 38.6 (11.2, 80.3) <0.001 68.1 (30.3, 89.4) 0.8 26.7 (3.0, 67.2) 0.1 2.5 (0, 39.0) 0.1 1.3 (0, 3.5) 0.3
 II 22.4 (12, 74.3)   41.2 (17.2, 84.2)   68.8 (21.6, 88.3)   40.8 (7.9, 83.3)   2.3 (0, 59.8)   1.4 (0.6, 4.6)  
 III 21.3 (6.8, 61.3)   40.4 (15.3, 69.7)   71.2 (21.4, 90.2)   28.8 (3.9, 75.1)   2.6 (0, 70.1)   1.5 (0, 16.0)  
 IV 27.6 (3.0, 90.5)   46.8 (10.8, 84.9)   70.5 (21.6, 93.9)   35.9 (3.1, 85.8)   2.2 (0, 51.8)   1.4 (0, 3.9)  
Comorbidities             
 None 29.5 (6.3, 74.3) 0.4 46.0 (20.2, 84.2) 0.3 74.8 (32.4, 93.9) 0.006 33.1 (5.6, 75.2) 0.6 2.5 (0, 39.9) 0.4 1.5 (0.4, 4.6) 0.1
 Mild 25.5 (3.0, 77.0)   43.3 (10.8, 84.9)   69.5 (21.6, 92.0)   35.4 (3.0, 85.8)   2.2 (0, 70.1)   1.4 (0, 16.0)  
 Moderate 23.0 (6.8, 90.5)   44.0 (15.0, 79.3)   69.2 (21.4, 92.2)   29.8 (3.5, 79.8)   2.2 (0, 59.8)   1.3 (0, 3.9)  
 Severe 30.5 (13.5,63.3)   44.6 (11.2, 80.3)   65.4 (21.6, 85.1)   43.0 (6.2, 83.3)   1.8 (0, 51.8)   1.2 (0, 3.9)  
Gender             
 Male 26.5 (3.0, 90.5) 0.2 45.6 (13.0, 84.9) 0.003 69.9 (21.4, 93.9) 0.4 36.1 (3.1, 85.8) 0.002 2.3 (0, 70.1) 0.9 1.4 (0, 3.9) 0.5
 Female 23.8 (6.3, 77.0)   40.5 (10.8, 68.9)   69.5 (21.6, 91.7)   25.4 (3.0, 75.1)   2.1 (0, 46.6)   1.4 (0, 16.0)  
  1. Distribution of methylation markers across patient characteristics. p-values calculated by Kruskal-Wallis tests. Methylation values are expressed as percentages